Group 1 - The company approved the use of raised funds from convertible bonds to replace self-raised funds previously invested in projects and to cover issuance costs, totaling RMB 5.959898 million (excluding tax) [2][7][9] - The total amount raised from the issuance of convertible bonds was RMB 56.25 million, with a net amount of RMB 55.4364976 million after deducting issuance costs of RMB 8.135024 million [2][12][26] - The funds were deposited into a designated account, and a tripartite supervision agreement was signed with the sponsor and banks [3][27][36] Group 2 - The company adjusted the investment amounts for certain projects due to the actual net amount raised being lower than previously disclosed, ensuring efficient use of funds [4][28][29] - The company pre-invested self-raised funds in projects before the raised funds were available, with specific amounts detailed for both project investments and issuance costs [6][75] - The board meetings held on December 18, 2025, approved various proposals related to the use of raised funds, including adjustments and replacements, without requiring shareholder approval [21][60][64] Group 3 - The company plans to provide a loan of RMB 27.82417 million from raised funds to its wholly-owned subsidiary for project implementation [12][15][21] - The loan will be used exclusively for the implementation of specific projects and will be managed under strict oversight [19][20][45] - The company will ensure that the cash management of idle raised funds does not affect the ongoing projects and will invest in low-risk, liquid products [34][39][48]

Core Points - The company will not distribute profits or increase share capital from reserves for the first half of 2025 [3] - The board of directors and supervisory board confirm the authenticity, accuracy, and completeness of the report [1][5] - The half-year report has not been audited [2] Company Overview - The company is Zhejiang Dongya Pharmaceutical Co., Ltd. [6] - The fourth board meeting was held on August 28, 2025, with all directors present [6][8] - The supervisory board meeting also took place on the same day, with all supervisors present [13][16] Financial Data - The actual amount raised from the convertible bonds was RMB 69 million, with a net amount of RMB 68.018 million after deducting fees [21] - As of June 30, 2025, the company had invested RMB 29 million in financial products, with RMB 20 million remaining unexpired [25] Important Matters - The company has not experienced significant changes in its operating conditions during the reporting period [4] - The company has not changed its convertible bond fundraising investment projects during the reporting period [28] Asset Impairment - The company has recognized an asset impairment provision totaling RMB 32.0236 million for the first half of 2025 [38] - This includes a bad debt provision of RMB 0.0877 million for accounts receivable and a provision of RMB 31.9804 million for inventory [39][41] - The impairment provision is in accordance with accounting standards and reflects the company's asset situation accurately [42]